Adding immunotherapy to chemotherapy may increase the risk of toxicity and likelihood of treatment discontinuation in patients with SCLC, a meta-analysis suggests.
Your search for non small cell lung cancer returned 25 results
Amivantamab can provide a long-term benefit in NSCLC patients with EGFR exon 20 insertions whose disease progressed on platinum-based chemotherapy, a study suggests.
Findings showed that treatment with cemiplimab-rwlc plus platinum-based chemotherapy demonstrated a statistically significant improvement in overall survival.
The approval was based on data from the KEYNOTE-091 trial.
Improvement seen compared with chemotherapy alone for first-line treatment of advanced non-small cell lung cancer.
The approval was based on data from a phase 3 POSEIDON study.
According to the CRL, the application could not be approved in its present form as additional data, including a randomized controlled trial, would be required.
Krazati is a highly selective and potent oral small molecule inhibitor of KRASG12C.
The accelerated approval was based on data from the phase 2 DESTINY-Lung02 trial that included adults with HER2-mutant metastatic NSCLC after 1 prior systemic therapy.
The full approval was based on data from an additional 63 adults with metastatic NSCLC with confirmed MET exon 14 skipping as well as 22 months of follow-up time.